UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Personalized Medicine in Ocular Fibrosis: Myth or Future Biomarkers

Yu-Wai-Man, C; Khaw, PT; (2016) Personalized Medicine in Ocular Fibrosis: Myth or Future Biomarkers. Advances in Wound Care , 5 (9) pp. 390-402. 10.1089/wound.2015.0677. Green open access

[thumbnail of wound%2E2015%2E0677.pdf]
Preview
Text
wound%2E2015%2E0677.pdf - Published Version

Download (926kB) | Preview

Abstract

SIGNIFICANCE: Fibrosis-related events play a part in the pathogenesis or failure of treatment of virtually all the blinding diseases around the world, and also account for over 40% of all deaths. It is well established that the eye and other tissues of some group of patients, for example Afro-Caribbean people, scar worse than others. However, there is a current lack of reliable biomarkers to stratify the risk of scarring and postsurgical fibrosis in the eye. RECENT ADVANCES: Recent studies using genomics, proteomics, metabolomics, clinical phenotyping, and high-resolution in vivo imaging techniques have revealed potential novel biomarkers to identify and stratify patients at risk of scarring in different fibrotic eye diseases. CRITICAL ISSUES: Most of the studies, to date, have been done in animals or small cohorts of patients and future research is needed to validate these results in large longitudinal human studies. Detailed clinical phenotyping and effective biobanking of patient tissues will also be critical for future biomarker research in ocular fibrosis. FUTURE DIRECTIONS: The ability to predict the risk of scarring and to tailor the antifibrotic treatment regimen to each individual patient will be an extremely useful tool clinically to prevent undertreating, or exposing patients to unnecessary treatments with potential side effects. An exciting future prospect will be to use new advances in genotyping, namely next-generation whole genome sequencing like RNA-Seq, to develop a customized gene chip in ocular fibrosis. Successful translation of future biomarkers to benefit patient care will also ultimately require a strong collaboration between academics, pharmaceutical, and biotech companies.

Type: Article
Title: Personalized Medicine in Ocular Fibrosis: Myth or Future Biomarkers
Open access status: An open access version is available from UCL Discovery
DOI: 10.1089/wound.2015.0677
Publisher version: http://dx.doi.org/10.1089/wound.2015.0677
Language: English
Additional information: Copyright © Cynthia Yu-Wai-Man and Peng Tee Khaw, 2016; Published by Mary Ann Liebert, Inc. This OpenAccess article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Institute of Ophthalmology
URI: https://discovery.ucl.ac.uk/id/eprint/1501139
Downloads since deposit
64Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item